Novo funds new line of attack on CMV herpes virus  

Danish biotech firm Inagen gains DKK 5m investment from Novo to bring drug candidate for treatment of cytomegalovirus (CMV) to the preclinical phase
Fledgling Danish biotech company Inagen has gained a DKK 5m (USD 940,000) investment from Novo A/S, the holding company in the Novo Group, and CAT Science Park in Denmark, to bring its primary drug candidate for the treatment of cytomegalovirus (CMV), a member of the herpes virus family, to the preclinical phase. According to Rizau, which reports the news, the technology could have a value of several billion dollars in the US alone.
More than half of all adults have had an infection with CMV virus. In the US, between 50% and 85% of the population have had a CMV virus by the time they are 40 years old, according to the Centers for Disease Control and Prevention. Once a person has had a CMV infection, the virus is usually inactive in the body. The problem is that it can be reactivated in people who have weakened immune systems, for example in patients with HIV or in connection with transplantation.
Thomas Kledal, MD of Inagen says: "There are major expenses associated with the treatment of the disease itself, and at the same time it is the largest infectious cause of congenital brain damage. So there are substantial social costs."
Inagen aims to develop a drug which can eliminate the infection by utilizing the fact that the virus creates certain proteins on the surface of infected cells, which act to prevent the body's immune defence systems from attacking the cell. Inagen's counter-strategy is to make these proteins into 'antennae' which can guide antiviral agents specifically to these cells while avoiding healthy cells.
Link > Inagen  

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×